114 related articles for article (PubMed ID: 17460029)
1. A natural variant of the heme-binding signature (R441C) resulting in complete loss of function of CYP2D6.
Klein K; Tatzel S; Raimundo S; Saussele T; Hustert E; Pleiss J; Eichelbaum M; Zanger UM
Drug Metab Dispos; 2007 Aug; 35(8):1247-50. PubMed ID: 17460029
[TBL] [Abstract][Full Text] [Related]
2. A model for human cytochrome P450 2D6 based on homology modeling and NMR studies of substrate binding.
Modi S; Paine MJ; Sutcliffe MJ; Lian LY; Primrose WU; Wolf CR; Roberts GC
Biochemistry; 1996 Apr; 35(14):4540-50. PubMed ID: 8605204
[TBL] [Abstract][Full Text] [Related]
3. Functional analysis of CYP2D6.31 variant: homology modeling suggests possible disruption of redox partner interaction by Arg440His substitution.
Allorge D; Bréant D; Harlow J; Chowdry J; Lo-Guidice JM; Chevalier D; Cauffiez C; Lhermitte M; Blaney FE; Tucker GT; Broly F; Ellis SW
Proteins; 2005 May; 59(2):339-46. PubMed ID: 15726636
[TBL] [Abstract][Full Text] [Related]
4. Identification of a meander region proline residue critical for heme binding to cytochrome P450: implications for the catalytic function of human CYP4B1.
Zheng YM; Fisher MB; Yokotani N; Fujii-Kuriyama Y; Rettie AE
Biochemistry; 1998 Sep; 37(37):12847-51. PubMed ID: 9737862
[TBL] [Abstract][Full Text] [Related]
5. A silent mutation (2939G>A, exon 6; CYP2D6*59) leading to impaired expression and function of CYP2D6.
Toscano C; Raimundo S; Klein K; Eichelbaum M; Schwab M; Zanger UM
Pharmacogenet Genomics; 2006 Oct; 16(10):767-70. PubMed ID: 17001296
[TBL] [Abstract][Full Text] [Related]
6. Analysis of genetic polymorphism and biochemical characterization of a functionally decreased variant in prostacyclin synthase gene (CYP8A1) in humans.
Cho SA; Rohn-Glowacki KJ; Jarrar YB; Yi M; Kim WY; Shin JG; Lee SJ
Arch Biochem Biophys; 2015 Mar; 569():10-8. PubMed ID: 25623425
[TBL] [Abstract][Full Text] [Related]
7. Binding of bufuralol, dextromethorphan, and 3,4-methylenedioxymethylamphetamine to wild-type and F120A mutant cytochrome P450 2D6 studied by resonance Raman spectroscopy.
Bonifacio A; Keizers PH; Commandeur JN; Vermeulen NP; Robert B; Gooijer C; van der Zwan G
Biochem Biophys Res Commun; 2006 May; 343(3):772-9. PubMed ID: 16563352
[TBL] [Abstract][Full Text] [Related]
8. Impact of incorporating the 2C5 crystal structure into comparative models of cytochrome P450 2D6.
Kirton SB; Kemp CA; Tomkinson NP; St-Gallay S; Sutcliffe MJ
Proteins; 2002 Nov; 49(2):216-31. PubMed ID: 12211002
[TBL] [Abstract][Full Text] [Related]
9. Identification of selectivity-determining residues in cytochrome P450 monooxygenases: a systematic analysis of the substrate recognition site 5.
Seifert A; Pleiss J
Proteins; 2009 Mar; 74(4):1028-35. PubMed ID: 18814300
[TBL] [Abstract][Full Text] [Related]
10. Prediction of binding modes for ligands in the cytochromes P450 and other heme-containing proteins.
Kirton SB; Murray CW; Verdonk ML; Taylor RD
Proteins; 2005 Mar; 58(4):836-44. PubMed ID: 15651036
[TBL] [Abstract][Full Text] [Related]
11. Understanding CYP2D6 interactions.
de Groot MJ; Wakenhut F; Whitlock G; Hyland R
Drug Discov Today; 2009 Oct; 14(19-20):964-72. PubMed ID: 19638317
[TBL] [Abstract][Full Text] [Related]
12. The importance of heterogeneous nuclear ribonucleoprotein K on cytochrome P450 2D2 gene regulation: its binding is reduced in Dark Agouti rats.
Sakai N; Sakamoto KQ; Fujita S; Ishizuka M
Drug Metab Dispos; 2009 Aug; 37(8):1703-10. PubMed ID: 19420131
[TBL] [Abstract][Full Text] [Related]
13. Structural rationalization of novel drug metabolizing mutants of cytochrome P450 BM3.
Stjernschantz E; van Vugt-Lussenburg BM; Bonifacio A; de Beer SB; van der Zwan G; Gooijer C; Commandeur JN; Vermeulen NP; Oostenbrink C
Proteins; 2008 Apr; 71(1):336-52. PubMed ID: 17957765
[TBL] [Abstract][Full Text] [Related]
14. Structure-based site of metabolism prediction for cytochrome P450 2D6.
Moors SL; Vos AM; Cummings MD; Van Vlijmen H; Ceulemans A
J Med Chem; 2011 Sep; 54(17):6098-105. PubMed ID: 21797232
[TBL] [Abstract][Full Text] [Related]
15. New cytochrome P450 2D6*56 allele identified by genotype/phenotype analysis of cryopreserved human hepatocytes.
Li L; Pan RM; Porter TD; Jensen NS; Silber P; Russo G; Tine JA; Heim J; Ring B; Wedlund PJ
Drug Metab Dispos; 2006 Aug; 34(8):1411-6. PubMed ID: 16679388
[TBL] [Abstract][Full Text] [Related]
16. Analysis of CYP2D6 substrate interactions by computational methods.
Ito Y; Kondo H; Goldfarb PS; Lewis DF
J Mol Graph Model; 2008 Feb; 26(6):947-56. PubMed ID: 17764997
[TBL] [Abstract][Full Text] [Related]
17. Molecular definitions of fatty acid hydroxylases in Arabidopsis thaliana.
Rupasinghe SG; Duan H; Schuler MA
Proteins; 2007 Jul; 68(1):279-93. PubMed ID: 17427946
[TBL] [Abstract][Full Text] [Related]
18. A refined substrate model for human cytochrome P450 2D6.
de Groot MJ; Bijloo GJ; Martens BJ; van Acker FA; Vermeulen NP
Chem Res Toxicol; 1997 Jan; 10(1):41-8. PubMed ID: 9074801
[TBL] [Abstract][Full Text] [Related]
19. Novel approach to predicting P450-mediated drug metabolism: development of a combined protein and pharmacophore model for CYP2D6.
de Groot MJ; Ackland MJ; Horne VA; Alex AA; Jones BC
J Med Chem; 1999 May; 42(9):1515-24. PubMed ID: 10229622
[TBL] [Abstract][Full Text] [Related]
20. Validation of model of cytochrome P450 2D6: an in silico tool for predicting metabolism and inhibition.
Kemp CA; Flanagan JU; van Eldik AJ; Maréchal JD; Wolf CR; Roberts GC; Paine MJ; Sutcliffe MJ
J Med Chem; 2004 Oct; 47(22):5340-6. PubMed ID: 15481972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]